Details
Stereochemistry | ABSOLUTE |
Molecular Formula | 2C11H18N2O4S3.2ClH.H2O |
Molecular Weight | 767.87 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.Cl.CC(C)CN[C@H]1CCS(=O)(=O)C2=C1C=C(S2)S(N)(=O)=O.CC(C)CN[C@H]3CCS(=O)(=O)C4=C3C=C(S4)S(N)(=O)=O
InChI
InChIKey=OMDSCSHWFCXOSL-UCJAQVTMSA-N
InChI=1S/2C11H18N2O4S3.2ClH.H2O/c2*1-7(2)6-13-9-3-4-19(14,15)11-8(9)5-10(18-11)20(12,16)17;;;/h2*5,7,9,13H,3-4,6H2,1-2H3,(H2,12,16,17);2*1H;1H2/t2*9-;;;/m00.../s1
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C11H18N2O4S3 |
Molecular Weight | 338.467 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Sezolamide (previously known as MK-417), a potent carbonic anhydrase inhibitor capable of reducing intraocular pressure after topical application, was under investigation for the treatment of glaucoma. . Sezolamide is the more potent of the two stereo isomers of MK-927 in inhibiting human carbonic anhydrase isoenzyme II, the isoenzyme found in ciliary processes. Sezolamide, the S-enantiomer of MK-927, has demonstrated activity in vitro approximately 80 times that of the R-enantiomer of MK-927 (concentrations of 0.54 nmolll and 44 nM, respectively, inhibiting activity of human carbonic anhydrase isoenzyme II by 50%). Clinically, sezolamide has also demonstrated greater activity than MK-927 both after single-dose and after twice daily administration in
patients.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1286720
A maximum intraocular pressure lowering
activity from time-matched baseline diurnal curve values
of about 20% was observed after multiple-dose twice daily administration of 1.8% sezolamide in patients with
primary open angle glaucoma or ocular hypertension.
Route of Administration:
Topical
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:28:51 GMT 2023
by
admin
on
Fri Dec 15 15:28:51 GMT 2023
|
Record UNII |
03K812H9OC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
03K812H9OC
Created by
admin on Fri Dec 15 15:28:51 GMT 2023 , Edited by admin on Fri Dec 15 15:28:51 GMT 2023
|
PRIMARY | |||
|
76966756
Created by
admin on Fri Dec 15 15:28:51 GMT 2023 , Edited by admin on Fri Dec 15 15:28:51 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |